U.S. National Library of MedicineNational Institutes of Health
Skip navigation
MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You
  FAQs Site Map About MedelinePlus Contact Us
español
HealthDay Logo

Japanese Researchers Develop New Smallpox Vaccine

No serious side effects are found in latest test, study reports
Printer-friendly version E-mail this page to a friend

HealthDay

By Robert Preidt

Tuesday, March 10, 2009

HealthDay news imageTUESDAY, March 10 (HealthDay News) -- A third-generation tissue-cultured smallpox vaccine shows promise, Japanese researchers report.

"The threat of smallpox bioterrorism has prompted reconsideration of the need for smallpox vaccination," the researchers noted. "Serious events associated with first-generation vaccines #133; have raised obstacles to vaccination campaigns in the United States."

Second-generation vaccines also cause a high rate of serious side effects, they said.

"Developing a vaccine that is safer than first-generation vaccines yet highly immunogenic [producing immunity or an immune response] is crucial to constructing a prevention plan in the event of bioterrorist attack," they added.

The researchers studied the clinical and immunological responses to the LC16m8 vaccine in 1,692 adults who had previously been vaccinated against smallpox and 1,529 adults who had not been vaccinated. LC16m8 is a live, attenuated (reduced in strength) vaccine.

Participants were examined 10 to 14 days after being vaccinated. The researchers found that antibodies developed in about 90 percent of those who had not been previously vaccinated, and an effective booster response occurred in 60 percent of those who had previously been vaccinated. None of the participants suffered serious side effects.

The study "offers supported evidence for the safety of LC16m8 vaccine in adults," wrote Dr. Tomoya Saito, of Keio University in Tokyo, and his colleagues."LC16m8 vaccine appears to be a viable alternative to first-, second- and other third-generation vaccines in a smallpox [bioterrorism] preparedness program."

The study appears in the March 11 issue of the Journal of the American Medical Association.


HealthDay

Copyright (c) 2009 ScoutNews, LLC. All rights reserved.


More News on this Date

Related MedlinePlus Pages: